Replicor Announces Four Appointments to Scientific Advisory Board
Doug Kornbrust, Ph.D., D.A.B.T.; Jennifer Lockridge, Ph.D.; Michael Roggendorf, M.D.; and Christian Trepo, M.D., Ph.D.
NEW YORK, April 27 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for Chronic Hepatitis B and D patients, today announced the appointments of four clinical experts to its new Scientific Advisory Board. The company has now completed its first series of proof of concept trials and continues to move toward next stage clinical development.
“We are pleased to mark our move to the next stage of research with these important Scientific Advisory Board appointments,” said Andrew Vaillant, Ph.D., and Chief Science Officer. “The addition of these expert individuals to our Advisory Board will help us gain further perspective into our data as we move into additional clinical trials in 2015 and beyond.”
Doug Kornbrust, Ph.D., D.A.B.T., has extensive experience in the planning and management of nonclinical portions of drug development programs, interactions with regulatory agencies and assistance with regulatory filings and he has held consultancy relationships with more than 170 pharmaceutical companies since 2002. Dr. Kornbrust was formerly Vice President and Scientific Director for Sierra Biomedical (now Charles River Laboratories Nevada) and Director of Toxicology, Pharmacokinetics and Metabolism at ISIS Pharmaceuticals, a leader in the development of oligonucleotide-based medicines.
Jennifer Lockridge, Ph.D. has more than fifteen years of consultancy experience in the oligonucleotide industry and specializes in the pharmacologic and pharmacokinetic evaluation of oligonucleotides. Dr. Lockridge has been involved in numerous pre-IND programs with oligonucleotide-based medicines and has successfully completed several United States FDA regulatory filings for the initiation of clinical studies. Dr. Lockridge was formerly Director of Project Management at Sirna Therapeutics where she was involved with all aspects of siRNA development programs at the pre- and post-IND stages.
Michael Roggendorf, M.D. is currently is a visiting Professor at the Institute for Virology, Technical University of Munich and serves on the Advisory Boards for the German Network of Competence for Hepatitis (Hep-Net) and the SFB / German – Chinese Transregio (SFB/TRR60) and was previously Director of the Institute of Virology, University of Duisburg – Essen and Head of the Diagnostic Laboratory of Viral Diseases and Hepatitis Research at the University of Munich. Dr. Roggendorf has authored more than 370 publications in the areas of virology and viral hepatitis. Recently he published several studies on immunomodulatory therapies in chronic hepatitis B. He is an expert reviewer for national and international research agencies, including the National Institutes of Health (USA).
Christian Trepo, M.D., Ph.D. is currently an Emeritus Professor at Claude Bernard University and a consultant at the Hepatogastroenterology department at Croix Rousse Hospital and acting Director of the Hepatitis Unit (INSERM 1052/CRCL), in Lyon, France. He has previously served in several important positions, including the Advisory Board for the European Association for the Study of the Liver (EASL), President of the French Association for the Study of the Liver, and Medical Coordinator of the Hepatitis C reference Center. Dr. Trepo graduated from the School of Medicine and Sciences of Lyon and Grenoble while completing Fogarty International Center fellowships in Virology at the New York Blood Center and in Hepatology at Cornell University Medical College. He has authored more than 750 articles in the areas of virology and viral hepatitis including hepatitis delta virus (HDV) from its initial finding, where he co-authored the milestone HDV discovery paper.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com or follow us on Twitter @replicorinc.